Harvard Framework Calls for Personalized Cancer Prevention Based on Individual Risk

Cancer survival is overwhelmingly determined by stage at diagnosis — yet the systems designed to catch cancer early are falling short. Only 13% of cancers are currently detected through guideline-based screening programs, and between 20% and 50% of cases first present in an emergency department, where the disease is often advanced and harder to treat. This gap represents a major, addressable failure in cancer control.

Published ahead of print in The Lancet, this framework paper from Harvard TH Chan School of Public Health and Dana-Farber Cancer Institute introduces the concept of Precision Prevention and Early Detection (PPED). Rather than applying uniform screening protocols to entire populations, PPED proposes asking four individualized questions: who carries elevated cancer risk, what preventive or screening intervention is appropriate for them, when and at what intensity should that intervention be applied, and how and where should it be delivered?

A key — and often overlooked — dimension of the PPED logic is de-escalation. Reducing or eliminating unnecessary screening in low-risk individuals is framed as equally important as intensifying surveillance in high-risk populations. Over-screening carries real costs: false positives, unnecessary procedures, patient anxiety, and wasted healthcare resources.

The framework cites hereditary cancer syndromes — such as BRCA1/2 mutations, Lynch syndrome, and Li-Fraumeni syndrome — as proof of concept. When cancer risk is sufficiently enriched and well-characterized, tailored surveillance and prevention strategies demonstrably save lives. The challenge is extending this logic to broader populations where risk is less clearly defined.

The author identifies health-system infrastructure and a specialized prevention workforce as the defining implementation challenges of the next decade. While the underlying science of risk stratification continues to mature — driven by polygenic risk scores, multi-cancer early detection blood tests, and biomarker research — the systems needed to act on that science must be built in parallel. For longevity-focused clinicians and health-conscious adults, the message is clear: population-level cancer control will increasingly require individualized risk assessment rather than generic age-based protocols.